Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00436553 · ClinicalTrials.gov registry record · Phase 3
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 321
- Enrollment target
NCT00436553 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 321 participants.
The verdict
NCT00436553, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 321 participants
- Enrollment target
Study Summary
This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration.
Interventions
- DRUG Ranibizumab
- DRUG Verteporfin Photodynamic Therapy
- DRUG Verteporfin Placebo
- DRUG Ranibizumab Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00436553
The ClinicalTrials.gov registry entry for NCT00436553 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ranibizumab is the first listed.
NCT00436553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00436553 about?
NCT00436553 is a clinical study titled "Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization". This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macul...
What is the current status of trial NCT00436553?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 321 participants. The study started on 2007-02. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00436553?
The interventions under investigation include: Ranibizumab (DRUG), Verteporfin Photodynamic Therapy (DRUG), Verteporfin Placebo (DRUG), Ranibizumab Placebo (DRUG).
Who is sponsoring clinical trial NCT00436553?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.